Match!
Y. Ohara
International University, Cambodia
19Publications
4H-index
55Citations
Publications 19
Newest
Published on Nov 1, 2017in Journal of The American Academy of Dermatology7.10
Yukari Zenke1
Estimated H-index: 1
(International University, Cambodia),
Y. Ohara4
Estimated H-index: 4
(International University, Cambodia)
+ 4 AuthorsHikaru Eto2
Estimated H-index: 2
(International University, Cambodia)
Background Patients with psoriatic arthritis (PsA) commonly present with nail manifestations; however, little is known about these manifestations. Objective This study investigated whether nail findings can be used to discriminate between PsA and psoriasis without arthritis. Methods We performed a retrospective analysis of 118 patients with PsA and 974 patients with psoriasis without arthritis who visited St. Luke's International Hospital (Tokyo, Japan) between July 2003 and February 2015. Patie...
Published on Jun 1, 2016in Annals of the Rheumatic Diseases14.30
A. Kitada , C. Min1
Estimated H-index: 1
+ 10 AuthorsTokutaro Tsuda
Background Sulfasalazine (SSZ) might have antibacterial effect, because it contains sulfa residue. However, its clinical usefulness in patients of rheumatoid arthritis (RA) has been unclear. Objectives Our aim was to evaluate whether SSZ could prevent bacterial infections especially in newly diagnosed RA patients. Methods The adult patients who were newly diagnosed with RA at St. Luke9s International Hospital, Tokyo, Japan from January 2006 to December 2013 were included in this retrospective op...
Published on Jun 1, 2016in Annals of the Rheumatic Diseases14.30
K. Takasugi , Masato Okada8
Estimated H-index: 8
+ 10 AuthorsH. Shimizu3
Estimated H-index: 3
Background Iguratimod, a member of the family of methanesulfonanilide, is a relatively new oral anti-rheumatic medication. Although most of the members of this family act as cyclooxygenase 2 inhibitor, iguratimod has been considered to be a novel immunomodulator agent. Little data exists regarding its safety and tolerability in patients with comorbid illnesses. Objectives To determine the safety and retention rate of Iguratimod in high risk patients. Methods For the period from December 2012 to ...
Published on Aug 1, 2015in The Journal of Rheumatology3.63
Y. Ohara4
Estimated H-index: 4
,
Mitsumasa Kishimoto14
Estimated H-index: 14
+ 9 AuthorsMari Higashiyama2
Estimated H-index: 2
Objective. To investigate the prevalence of psoriatic arthritis (PsA) in Japanese patients with psoriasis. Methods. A multicenter, noninterventional, retrospective cross-sectional study was conducted at 3 tertiary care centers in Japan. PsA was diagnosed by rheumatologists based on clinical findings. Prevalence of PsA, clinical characteristics, comorbidities, and treatment patterns were examined. Results. PsA was identified in 431 of 3021 patients with psoriasis, with a mean prevalence of 14.3% ...
Published on Jun 1, 2014in Annals of the Rheumatic Diseases14.30
Ryo Rokutanda3
Estimated H-index: 3
,
Y. Haji + 9 AuthorsA. Takeda
Background We previously reported successful use of multi-target therapy using tacrolimus (TAC), mizoribine (MZR), and prednisolone for systemic lupus erythematosus[1]. More data is needed to confirm usefulness of this combination therapy for severe disease forms such as lupus nephritis. Objectives To examine efficacy and safety of multi-target therapy for lupus nephritis. Methods Retrospective review of electric medical record was performed for all the 28 patients who received multi-target usin...
Published on Jun 1, 2014in Annals of the Rheumatic Diseases14.30
Tatsuo Kobayashi3
Estimated H-index: 3
,
Mitsumasa Kishimoto14
Estimated H-index: 14
+ 8 AuthorsMasato Okada8
Estimated H-index: 8
Background An association between Behcet9s syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. A few reports from Taiwan, Greece, and Japan were also published that indicated HLA-A*26 is associated with BS independently from HLA-B*51. Recently, we reported the strong associations between HLA-A*26 and BS from our cohort led by rheumatologist. But our previous study may have some limitations because the patients were diagnosed by clinical manifestations and expert opi...
Published on Jun 1, 2014in Annals of the Rheumatic Diseases14.30
Yasuhiro Suyama3
Estimated H-index: 3
,
Mitsumasa Kishimoto14
Estimated H-index: 14
+ 7 AuthorsMasato Okada8
Estimated H-index: 8
Background Biologics are widely used for the treatment of rheumatic diseases because of the efficacy, but careful surveillance and prophylactic measures are necessary to reduce the incidence of adverse events, especially infections. Quality indicator (QI) has been received an increasing attention in rheumatology field and several guidelines for the prevention of biologic agents-related infections have been published. However, few studies have reported the status of the implementation as well as ...
Published on Jun 1, 2014in Annals of the Rheumatic Diseases14.30
Ryo Rokutanda3
Estimated H-index: 3
,
Y. Haji + 9 AuthorsYukio Matsui1
Estimated H-index: 1
Background There have been little data regarding epidemiology and usefulness of autoantibodies in general population. Objectives The purpose of this study is to describe epidemiological data about rheumatoid factor (RF) and anti-CCP antibody (ACPA) in Japanese general population and evaluate the usefulness of ACPA for detecting undiagnosed RA at annual health checkup. Methods During the period from November 2013 to January 2014, we checked RF and ACPA in all the female who visited St. Luke9s Int...
Published on Jan 1, 2014in Rheumatology International2.20
Ryo Rokutanda3
Estimated H-index: 3
,
Mitsumasa Kishimoto14
Estimated H-index: 14
+ 6 AuthorsMasato Okada8
Estimated H-index: 8
The objective of this study was to examine the safety and efficacy of mizoribine (MZR), an inhibitor of inosine monophosphate dehydrogenase, in patients with connective tissue diseases (CTDs) other than rheumatoid arthritis. We identified all patients who had ever been treated with MZR for CTDs at our institution during the period from January 2001 to May 2011. A retrospective review of medical records was performed to evaluate safety and efficacy of MZR. A total of 63 patients (13 induction and...
12